Superworth

Sera Prognostics SERA

Medical - Diagnostics & Research, Healthcare
$1.99
−2.45%
Market cap
$78.5M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
n/m
a sliver of sales
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$70K
−35% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−35.9%

Sera Prognostics' trailing earnings are negative, so it has no PE. Revenue was $70K over the last twelve months, down 35% on a year earlier.

Charts

Financials

Income statement for SERA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$42K−52%$41K−37%$0$24K−81%$29K−31%$24K−42%$38K$17K−29%$16K−45%$10K−58%$14K−63%$30K+77%
Cost of revenue$44K−24%$24K$17K−73%$20K−75%$13K−71%$32K+33%$40K+135%$41K+105%$41K+215%$42K+31%$42K+5%$50K+22%
Gross profit−$2K$17K−$17K$4K−91%$16K−$8K−$2K−88%−$24K−$25K−$32K+300%−$28K+1300%−$20K−17%
R&D$3.5M−15%$3.9M+12%$3.7M−10%$4.4M+20%$3.5M−1%$3.1M−19%$3.3M−10%$3.3M−24%$3.3M−6%$3.2M+3%$3M−9%$3.5M+5%
SG&A$4.6M−34%$5M−28%$5.4M−26%$4.9M−38%$5.4M+16%$6.3M+26%$5.9M+10%$6M+23%$5.7M+6%$5.7M−9%$6.3M+7%$6.5M+9%
−$8.2M−27%−$8.8M−15%−$9.1M−20%−$9.3M−19%−$8.9M+8%−$9.4M+7%−$9.3M+2%−$9.3M+1%−$9M+1%−$9M−5%−$9.4M+1%−$10M+7%
Interest expense$14K−33%$11K−39%$9K−44%$8K−43%$5K−64%$6K−46%$4K−56%$2K−75%$2K−60%$1K−83%$2K−50%$2K+0%
Net income−$7.2M−33%−$7.9M−19%−$8.1M−23%−$8.3M−21%−$7.9M+10%−$8.6M+8%−$8.2M+1%−$8M−3%−$7.8M−1%−$7.9M−8%−$8.4M+3%−$9.1M+14%
−$0.23−34%−$0.25−19%−$0.25−27%−$0.25−27%−$0.24+4%−$0.25+0%−$0.20−20%−$0.16−36%−$0.16−33%−$0.16−36%−$0.17−15%−$0.18+13%
31.3M+1%31.4M+1%32.2M+4%32.9M+6%33.5M+7%33.9M+8%42M+30%49.1M+49%49.5M+48%50M+47%50.3M+20%50.5M+3%

Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Gross profit: 20 periods, Q1 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.

R&D: Q1 FY20: 6 months less the 3 months printed beside them.

SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Operating income: Q1 FY20: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Sera Prognostics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SERASera Prognostics$78.5Mn/mn/an/m−35%n/m
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
ICCCImmucell$95.9M132×44.1×3.1×+8%2.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
ATNMActinium Pharmaceuticals$45M4.0×3.3×n/mn/mn/m
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
PLXProtalix BioTherapeutics$206.3M11.1×33.6×2.6×+30%23.5%
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
Peer median$84.7M12.8×18.0×1.3×+7%6.8%

More on Sera Prognostics

Each number over time

Its groups

About

Industry
Medical - Diagnostics & Research
Sector
Healthcare

Valuation data, not investment advice. Prices as of .